Cosunter(SZ:300436) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2026-01-06 07:51Group 1 - The company, Fujian Guangshengtang Pharmaceutical Co., Ltd., is participating in a national major science and technology project aimed at exploring new treatment options for chronic hepatitis B, which has received official approval from the National Health Commission [2][3]. - The project, titled "Research on New Combined Treatment Plans for Clinical Cure of Chronic Hepatitis B," is led by Southern Medical University and will run from December 2025 to November 2028, focusing on improving clinical cure rates and developing guidelines for hepatitis B treatment in China [3][4]. - The company is involved in two specific research topics within the project, which include studies on the use of antisense oligonucleotides and multi-target sequential therapies to enhance clinical cure rates for hepatitis B [4]. Group 2 - The project is significant as it aligns with national health strategies, including the "Healthy China 2030" plan, and aims to strengthen the country's capacity to respond to emerging infectious diseases [4][5]. - Data from Polaris Observatory indicates that there are approximately 79.74 million HBV carriers in China, with chronic hepatitis B patients numbering between 20 million and 30 million, highlighting the public health challenge posed by this disease [5]. - The national action plan for hepatitis B prevention and treatment aims for an 80% diagnosis rate and an 80% treatment rate for chronic hepatitis B patients by 2030, marking a shift towards a focus on "cure" [6]. Group 3 - As a participant in the national project, the company will collaborate closely with leading research teams and clinical centers, which may enhance its competitive edge in the hepatitis B treatment sector [7]. - The company's innovative drugs, GST-HG141 and GST-HG131, have been recognized as breakthrough treatment candidates and are currently undergoing clinical trials, with GST-HG141 having successfully enrolled its first participant in a Phase III trial [7]. - The sequential combination therapy plan, part of the company's "Hepatitis B Summit Plan," is positioned as an exploratory research scheme within the national project, which could facilitate the clinical development and commercialization of its innovative drugs [7].